可服用药物的标ATAD2增强了恶性进展,并与E2F1合作,对质瘤中PDK1表达的上调调节
Shenghua Zhuo1, Liangwang Yang1, Zhimin Chen2
1International Center for Aging and Cancer, Department of Neurosurgery, The First Affiliated Hospital of Hainan Medical University (Hainan Academy of Medical Sciences), Haikou, Hainan 571199, China.
含有AAA域的ATPase家族蛋白2 (ATAD2) 通过增强细胞增殖,迁移和入侵来促进质瘤恶性. 针对ATAD2,以及E2F1和pyruvate dehydrogenase kinase 1 (PDK1),为质瘤患者提供了一个潜在的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 质瘤的死亡率和残疾率很高,需要新的治疗点.
- 癌症丸抗原 (CTA) 是有前途的目标,但ATPase家族AAA域含蛋白2 (ATAD2) 在质瘤中的作用仍未得到充分研究.
研究的目的:
- 调查ATAD2在质瘤进展中的作用.
- 为了确定下游目标和分子机制,由ATAD2调节在质母细胞瘤 (GBM).
主要方法:
- 在LN229细胞系的体外和体内实验.
- 用RNA测序和蛋白质组学来识别ATAD2下游目标.
- 在临床前模型中评估细胞增殖,迁移,入侵,瘤生长和存活率.
主要成果:
- 在质母细胞瘤 (GBM) 中观察到升高的ATAD2表达.
- ATAD2敲击降低了GBM细胞的增殖,迁移和入侵,降低了瘤的生长,并改善了小鼠的生存率.
- 确定了ATAD2,E2F转录因子1 (E2F1) 和pyruvate dehydrogenase kinase 1 (PDK1) 之间的积极反循环,增强了PDK1转录.
结论:
- ATAD2在质瘤恶性进展中起着至关重要的作用.
- ATAD2-E2F1-PDK1轴代表了质瘤治疗的潜在治疗目标.
- ATAD2,E2F1和PDK1的高表达与患者预后较差相关.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
09:24Generation of Microtumors Using 3D Human Biogel Culture System and Patient-derived Glioblastoma Cells for Kinomic Profiling and Drug Response Testing
Published on: June 9, 2016
相关概念视频
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Mitogens and the Cell Cycle
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Abnormal Proliferation
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
